Filing Flows › Regeneron Pharmaceuticals (REGN) › Free cash flow
Regeneron Pharmaceuticals (REGN) free cash flow by quarter
Regeneron Pharmaceuticals' free cash flow was $1.5B in Q3 2026 (third quarter 2026), +159% from Q2 2026. Over the last 7 quarters it ranged from $573M (Q2 2026) to $1.5B (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.5B | +159% | +5% |
| Q2 2026 | $573M | -32% | -38% |
| Q1 2026 | $848M | -8% | +4% |
| Q4 2025 | $922M | -35% | — |
| Q3 2025 | $1.4B | +53% | — |
| Q2 2025 | $925M | +13% | — |
| Q1 2025 | $816M | — | — |
Q3 2026 at a glance
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
What is Regeneron Pharmaceuticals' free cash flow?
Regeneron Pharmaceuticals' free cash flow was $1.5B in Q3 2026 (third quarter 2026), +159% from Q2 2026.
How has Regeneron Pharmaceuticals' free cash flow changed?
Over the last 7 quarters it ranged from $573M (Q2 2026) to $1.5B (Q3 2026).
Q3 2026 results → · How Regeneron Pharmaceuticals makes money →